New Oral Anti-Cancer Drugs and Medication Safety

Schlichtig K, Duerr P, Dörje F, Fromm M (2019)

Publication Type: Journal article, Review article

Publication year: 2019

Journal

Deutsches Ärzteblatt international Deutscher Ärzte-Verlag

Book Volume: 116

Pages Range: 775-+

Journal Issue: 46

DOI: 10.3238/arztebl.2019.0775

Abstract

Background: Many oral anti-cancer drugs have come onto the market in the past 20 years. For example. kinase inhibitors, such as the BCR-ABL and BRAF inhibitors, have markedly improved the treatment of chronic myeloid leukemia and melanoma. In this review, we discuss the special challenges posed by poor adherence, drug-drug interactions with other substances, and side effects, among other problems, and the ways in which these challenges can be met.

Authors with CRIS profile

Katja Geßner Lehrstuhl für Klinische Pharmakologie und Klinische Toxikologie Frank Dörje Naturwissenschaftliche Fakultät Martin Fromm Lehrstuhl für Klinische Pharmakologie und Klinische Toxikologie

How to cite

APA:

Schlichtig, K., Duerr, P., Dörje, F., & Fromm, M. (2019). New Oral Anti-Cancer Drugs and Medication Safety. Deutsches Ärzteblatt international, 116(46), 775-+. https://doi.org/10.3238/arztebl.2019.0775

MLA:

Schlichtig, Katja, et al. "New Oral Anti-Cancer Drugs and Medication Safety." Deutsches Ärzteblatt international 116.46 (2019): 775-+.

BibTeX: Download